Otis W. Brawley
Otis W. Brawley's purchase track record
Otis W. Brawley has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/31/2025 | LYEL | $20K | -17.8% | +39.1% | +18.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Transaction History
| INCY | ▲ Buy | Grant | 1,642 | $0 | 6/8/2026 | View on chart |
| A | ▲ Buy | Grant | 888 | $99K | 3/19/2026 | View on chart |
| A | ▲ Buy | Grant | 2,158 | $241K | 3/19/2026 | View on chart |
| INCY | ▲ Buy | Grant | 2,518 | $0 | 6/10/2025 | View on chart |
| LYEL | ▲ Buy | Open Market | 35,640 | $20K | 3/31/2025 | View on chart |
| A | ▲ Buy | Grant | 1,819 | $220K | 3/14/2025 | View on chart |
| A | ▲ Buy | Grant | 812 | $98K | 3/14/2025 | View on chart |
| INCY | ▲ Buy | Grant | 2,830 | $0 | 6/12/2024 | View on chart |
| A | ▲ Buy | Grant | 1,678 | $247K | 3/15/2024 | View on chart |
| A | ▲ Buy | Grant | 750 | $111K | 3/15/2024 | View on chart |
| INCY | ▲ Buy | Grant | 2,505 | $0 | 6/14/2023 | View on chart |
| A | ▲ Buy | Grant | 1,658 | $227K | 3/16/2023 | View on chart |
| A | ▲ Buy | Grant | 741 | $101K | 3/16/2023 | View on chart |
| INCY | ▲ Buy | Grant | 2,144 | $0 | 6/15/2022 | View on chart |
| A | ▲ Buy | Grant | 797 | $109K | 3/17/2022 | View on chart |
| A | ▲ Buy | Grant | 1,785 | $244K | 3/17/2022 | View on chart |
| A | ▲ Buy | Grant | 179 | $29K | 11/18/2021 | View on chart |
| A | ▲ Buy | Grant | 404 | $66K | 11/18/2021 | View on chart |
| INCY | ▲ Buy | Grant | 1,255 | $0 | 9/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes
Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.